 | Up a level |
2021
Kunzmann, Volker, Siveke, Jens T., Alguel, Hana, Goekkurt, Eray, Siegler, Gabriele, Martens, Uwe, Waldschmidt, Dirk, Pelzer, Uwe 
ORCID: 0000-0001-9213-2737, Fuchs, Martin, Kullmann, Frank, Boeck, Stefan, Ettrich, Thomas J., Held, Swantje, Keller, Ralph, Klein, Ingo, Germer, Christoph-Thomas, Stein, Hubert, Friess, Helmut, Bahra, Marcus, Jakobs, Ralf, Hartlapp, Ingo and Heinemann, Volker
(2021).
Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Lancet Gastroenterol. Hepatol., 6 (2).
S. 128 - 139.
SAN DIEGO:
ELSEVIER INC.
ISSN 2468-1253
2018
Kunzmann, Volker, Martens, Uwe Marc, Alguel, Hana, Siveke, Jens T., Goekkurt, Eray, Pelzer, Uwe ORCID: 0000-0001-9213-2737, Siegler, Gabriele Margareta, Hennes, Elke, Waldschmidt, Dirk, Jakobs, Ralf, Ferenczy, Peter, Keller, Ralph, Boeck, Stefan Hubert, Kullmann, Frank, Kapp, Markus and Germer, Christoph Thomas
(2018).
Secondary resectability in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- versus FOLFIRINOX-based induction chemotherapy: Interim results of a randomized phase II AIO trial (NEOLAP).
J. Clin. Oncol., 36 (4).
ALEXANDRIA:
AMER SOC CLINICAL ONCOLOGY.
ISSN 1527-7755